Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib gel in adults with prurigo nodularis
ChiCTR2500096434Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib in prurigo nodularis (PN) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Safety. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2500096434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096434.